UNCY Q3 EPS Forecast Lifted by Brookline Capital Markets

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Research analysts at Brookline Capital Markets lifted their Q3 2026 earnings per share estimates for shares of Unicycive Therapeutics in a note issued to investors on Tuesday, June 30th. Brookline Capital Markets analyst K. Raja now forecasts that the company will post earnings per share of ($0.30) for the quarter, up from their prior estimate of ($0.34). The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.32) per share. Brookline Capital Markets also issued estimates for Unicycive Therapeutics’ FY2027 earnings at $3.35 EPS, FY2028 earnings at $3.14 EPS and FY2029 earnings at $4.09 EPS.

A number of other analysts also recently issued reports on the stock. Benchmark dropped their price objective on shares of Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating for the company in a report on Wednesday. Weiss Ratings raised Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, June 9th. Guggenheim restated a “buy” rating and set a $37.00 price target (down from $40.00) on shares of Unicycive Therapeutics in a research report on Wednesday, May 13th. Wall Street Zen lowered Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, June 27th. Finally, B. Riley Financial reiterated a “buy” rating and set a $22.00 price objective on shares of Unicycive Therapeutics in a research report on Tuesday. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Unicycive Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $27.40.

Unicycive Therapeutics Price Performance

UNCY stock opened at $5.73 on Friday. The firm has a 50 day simple moving average of $7.43 and a two-hundred day simple moving average of $6.81. The stock has a market cap of $156.94 million, a PE ratio of -2.59 and a beta of 1.79. Unicycive Therapeutics has a one year low of $3.71 and a one year high of $8.74.

Unicycive Therapeutics (NASDAQ:UNCY) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.54) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.08).

Institutional Investors Weigh In On Unicycive Therapeutics

Several institutional investors have recently bought and sold shares of the stock. Lazard Asset Management LLC purchased a new position in Unicycive Therapeutics in the 2nd quarter worth approximately $55,000. JPMorgan Chase & Co. boosted its stake in shares of Unicycive Therapeutics by 11,698.4% during the second quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after purchasing an additional 21,525 shares during the period. Renaissance Technologies LLC bought a new position in shares of Unicycive Therapeutics in the first quarter worth approximately $161,000. Citadel Advisors LLC bought a new position in shares of Unicycive Therapeutics in the third quarter worth approximately $182,000. Finally, Bank of America Corp DE increased its stake in shares of Unicycive Therapeutics by 19,327.6% in the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock worth $194,000 after buying an additional 29,378 shares during the period. 40.42% of the stock is currently owned by hedge funds and other institutional investors.

Unicycive Therapeutics News Roundup

Here are the key news stories impacting Unicycive Therapeutics this week:

• Negative Sentiment: Investors are reacting to reports that Unicycive received a second FDA Complete Response Letter, with articles saying the agency cited third-party manufacturing deficiencies. That keeps regulatory uncertainty high and appears to be the main pressure on the stock. Unicycive Therapeutics (UNCY) Is Down 33.1% After FDA CRL Cites Third-Party Manufacturing Deficiencies
• Negative Sentiment: Multiple law firms, including Kirby McInerney, Bragar Eagel & Squire, and Block & Leviton, announced securities-fraud investigations tied to the FDA update, which can add overhang and worsen investor sentiment. UNICYCIVE THERAPEUTICS, INC. INVESTOR ALERT
• Negative Sentiment: HC Wainwright and Noble Financial sharply reduced near-term earnings estimates for 2026 and 2027, signaling more caution around the company’s path to profitability even though both firms kept bullish ratings. MarketBeat UNCY analyst updates
• Neutral Sentiment: Despite the estimate cuts, analysts such as HC Wainwright and Noble Financial still have Buy/Outperform ratings and price targets well above the current share price, which may help limit downside if investors focus on longer-term commercialization potential. MarketBeat UNCY analyst updates

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.